it has to be supplied in sufficient amounts in the diet
Tirzepatide is contraindicated in pregnancy, and weight gain could be an early sign of pregnancy
They found that intestinal flora may mediate the release of the intestinal hormone GLP-1 through the short-chain fatty acid (SCFA)-GPCR pathway, thereby increasing satiety and slowing gastric emptying, ultimately reducing obesity
From our current clinical experience, the patients who typically require higher doses to respond, are typically the patients who have a higher insulin resistance profile
Patients start at 2.5 mg weekly for 4 weeks, then escalate by 2.5 mg increments every 4 weeks as tolerated until reaching maintenance dose, typically 10 mg or 15 mg
Renoprotective effects of SGLT2 inhibitors